A case of hypophosphatemic osteomalacia associated with low-dose adefovir dipivoxil treatment.
- Author:
Ki Deok YOO
1
;
Jong Heon JEONG
;
Soo Kyung CHO
;
Gheun Ho KIM
;
Ho Soon CHOI
;
Dong Sun KIM
;
Jae Bum JUN
Author Information
1. Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Adefovir dipivoxil;
Nephrotoxicity;
Hypophosphatemia;
Osteomalacia
- MeSH:
Adenine;
Alkaline Phosphatase;
Animals;
Ankle;
Creatinine;
Densitometry;
Hepatitis B virus;
Hepatitis B, Chronic;
Humans;
Hypophosphatemia;
Knee;
Middle Aged;
Organophosphonates;
Osteomalacia;
Osteoporosis;
Stress, Psychological
- From:Korean Journal of Medicine
2010;78(2):261-265
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Adefovir dipivoxil (ADV) effectively inhibits lamivudine-resistant hepatitis B virus replication. Hypophosphatemia and elevated serum creatinine are ADV-related nephrotoxicity caused by high-dose ADV. Hypophosphatemic osteomalacia is very rare and is induced by low-dose ADV. A 61-year-old man suffering from chronic hepatitis B manifested with generalized myalgia and bone pain, especially in both ankles and knees. He had been administered ADV for 56 months, since lamivudine-resistant HBV was detected. He developed severe hypophosphatemia and elevated serum alkaline phosphatase levels with a high bone fraction. Bone densitometry and a whole-body bone scan revealed osteoporosis and multiple hot uptake lesions. Blood chemistry and clinical symptoms improved after discontinuing the ADV.
